1.	Yunzhi as Dietary Supplement in Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: YUNZHI-BC, NCT00647075
2.	Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: simcere002, simcere0802, NCT00813332
3.	A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML22780, 2009-014279-37, NCT01094184
4.	Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEICAM/2009-02, 2010-022689-29, NCT01298193
5.	A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25288, NCT01301729
6.	MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Phase: Phase IV Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P0334, NCT01501487
7.	Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Phase: Phase IV Type: Supportive care, Treatment Status: Approved-not yet active Age: 20 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-91, NCT01571518
8.	An Open-label, Multi-center Phase ? Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 20 to 70 Sponsor: Other Protocol IDs: 4-2011-0068, NCT01660542
9.	Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Phase: Phase IV Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: BD-IC-IV08, NCT01665417
10.	STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial Phase: Phase III, Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: CDR0000455008, MRC-STAMPEDE, EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476
11.	Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Active Age: 17 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: PH-CP010, NCT00518869
12.	Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 59 Sponsor: Other Protocol IDs: M09TNM, 2009-015238-31, NCT01057069
13.	Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AAAD6491, NCT01065870
14.	Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: BREC-AGC, NCT01206218
15.	5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FLOT4, NCT01216644
16.	Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 9thShanghai, 10DZ1951300, NCT01434394
17.	Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EGC-0254/87/2011, UML-EGC-2011, NCT01523015
18.	TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: TPF for resectable OSCC, 2007BAI18B03, NCT01542931
19.	External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: GU004-11, NCT01603420
20.	Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: Postmenopausal Sponsor: Other Protocol IDs: TENBC, NCT01648608
21.	Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 20111220, NCT01689558
22.	Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0301, 1209-1184, NCT01774578
23.	ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: WSG-AM06 / ADAPT HR+/HER2-, NCT01779206
24.	Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 97-1967A3, NCT01802021
25.	Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: RTOG 1216, NCI-2013-00500, U10CA021661, NCT01810913